These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37565139)

  • 1. Protease XIV abolishes NHE inhibition by empagliflozin in cardiac cells.
    Chen S; Schumacher CA; Van Amersfoorth SCM; Fiolet JWT; Baartscheer A; Veldkamp MW; Coronel R; Zuurbier CJ
    Front Physiol; 2023; 14():1179131. PubMed ID: 37565139
    [No Abstract]   [Full Text] [Related]  

  • 2. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na
    Uthman L; Baartscheer A; Bleijlevens B; Schumacher CA; Fiolet JWT; Koeman A; Jancev M; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Diabetologia; 2018 Mar; 61(3):722-726. PubMed ID: 29197997
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Empagliflozin mitigates cardiac hypertrophy through cardiac RSK/NHE-1 inhibition.
    Chen S; Overberg K; Ghouse Z; Hollmann MW; Weber NC; Coronel R; Zuurbier CJ
    Biomed Pharmacother; 2024 May; 174():116477. PubMed ID: 38522235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Empagliflozin Decreases Lactate Generation in an NHE-1 Dependent Fashion and Increases α-Ketoglutarate Synthesis From Palmitate in Type II Diabetic Mouse Hearts.
    Zhang H; Uthman L; Bakker D; Sari S; Chen S; Hollmann MW; Coronel R; Weber NC; Houten SM; van Weeghel M; Zuurbier CJ
    Front Cardiovasc Med; 2020; 7():592233. PubMed ID: 33344518
    [No Abstract]   [Full Text] [Related]  

  • 5. Delayed ischaemic contracture onset by empagliflozin associates with NHE1 inhibition and is dependent on insulin in isolated mouse hearts.
    Uthman L; Nederlof R; Eerbeek O; Baartscheer A; Schumacher C; Buchholtz N; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Cardiovasc Res; 2019 Aug; 115(10):1533-1545. PubMed ID: 30649212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart.
    Chung YJ; Park KC; Tokar S; Eykyn TR; Fuller W; Pavlovic D; Swietach P; Shattock MJ
    Cardiovasc Res; 2021 Dec; 117(14):2794-2806. PubMed ID: 33135077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute SGLT-2i treatment improves cardiac efficiency during myocardial ischemia independent of Na
    Baker HE; Tune JD; Mather KJ; Blaettner BS; Clark HE; Li F; Li X; Kowala MC; Fliegel L; Goodwill AG
    Int J Cardiol; 2022 Sep; 363():138-148. PubMed ID: 35753619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin inhibits Na
    Trum M; Riechel J; Lebek S; Pabel S; Sossalla ST; Hirt S; Arzt M; Maier LS; Wagner S
    ESC Heart Fail; 2020 Dec; 7(6):4429-4437. PubMed ID: 32946200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Empagliflozin inhibits angiotensin II-induced hypertrophy in H9c2 cardiomyoblasts through inhibition of NHE1 expression.
    Abdulrahman N; Ibrahim M; Joseph JM; Elkoubatry HM; Al-Shamasi AA; Rayan M; Gadeau AP; Ahmed R; Eldassouki H; Hasan A; Mraiche F
    Mol Cell Biochem; 2022 Jun; 477(6):1865-1872. PubMed ID: 35334035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events.
    Spigoni V; Fantuzzi F; Carubbi C; Pozzi G; Masselli E; Gobbi G; Solini A; Bonadonna RC; Dei Cas A
    Cardiovasc Diabetol; 2020 Apr; 19(1):46. PubMed ID: 32264868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin reduces oxidative stress through inhibition of the novel inflammation/NHE/[Na
    Uthman L; Li X; Baartscheer A; Schumacher CA; Baumgart P; Hermanides J; Preckel B; Hollmann MW; Coronel R; Zuurbier CJ; Weber NC
    Biomed Pharmacother; 2022 Feb; 146():112515. PubMed ID: 34896968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin decreases myocardial cytoplasmic Na
    Baartscheer A; Schumacher CA; Wüst RC; Fiolet JW; Stienen GJ; Coronel R; Zuurbier CJ
    Diabetologia; 2017 Mar; 60(3):568-573. PubMed ID: 27752710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1.
    Silva Dos Santos D; Turaça LT; Coutinho KCDS; Barbosa RAQ; Polidoro JZ; Kasai-Brunswick TH; Campos de Carvalho AC; Girardi ACC
    Sci Rep; 2023 May; 13(1):8689. PubMed ID: 37248416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients.
    Uthman L; Baartscheer A; Schumacher CA; Fiolet JWT; Kuschma MC; Hollmann MW; Coronel R; Weber NC; Zuurbier CJ
    Front Physiol; 2018; 9():1575. PubMed ID: 30519189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Hypoxia and Acidosis on Cardiac Electrophysiology and Hemodynamics. Is NHE-Inhibition by Cariporide Still Advantageous?
    Salameh A; Zöbisch H; Schröder B; Vigelahn J; Jahn M; Abraham G; Seeger J; Dähnert I; Dhein S
    Front Physiol; 2020; 11():224. PubMed ID: 32265732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin attenuates arrhythmogenesis in diabetic cardiomyopathy by normalizing intracellular Ca
    Kadosaka T; Watanabe M; Natsui H; Koizumi T; Nakao M; Koya T; Hagiwara H; Kamada R; Temma T; Karube F; Fujiyama F; Anzai T
    Am J Physiol Heart Circ Physiol; 2023 Mar; 324(3):H341-H354. PubMed ID: 36607794
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydrogen peroxide induced impairment of post-ischemic ventricular function is prevented by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide).
    Myers ML; Farhangkhoee P; Karmazyn M
    Cardiovasc Res; 1998 Nov; 40(2):290-6. PubMed ID: 9893722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulation of the plasma membrane Na+/H+ exchanger NHE1 by sustained intracellular acidosis. Evidence for a novel mechanism mediated by the ERK pathway.
    Haworth RS; McCann C; Snabaitis AK; Roberts NA; Avkiran M
    J Biol Chem; 2003 Aug; 278(34):31676-84. PubMed ID: 12791686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis.
    Chung CC; Lin YK; Chen YC; Kao YH; Yeh YH; Trang NN; Chen YJ
    Cardiovasc Diabetol; 2023 Feb; 22(1):27. PubMed ID: 36747205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac Sodium/Hydrogen Exchanger (NHE11) as a Novel Potential Target for SGLT2i in Heart Failure: A Preliminary Study.
    Pérez-Carrillo L; Aragón-Herrera A; Giménez-Escamilla I; Delgado-Arija M; García-Manzanares M; Anido-Varela L; Lago F; Martínez-Dolz L; Portolés M; Tarazón E; Roselló-Lletí E
    Pharmaceutics; 2022 Sep; 14(10):. PubMed ID: 36297433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.